Masashi Taki

1.6k total citations · 1 hit paper
58 papers, 1.1k citations indexed

About

Masashi Taki is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Masashi Taki has authored 58 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hematology, 11 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Masashi Taki's work include Hemophilia Treatment and Research (31 papers), Platelet Disorders and Treatments (24 papers) and Blood Coagulation and Thrombosis Mechanisms (16 papers). Masashi Taki is often cited by papers focused on Hemophilia Treatment and Research (31 papers), Platelet Disorders and Treatments (24 papers) and Blood Coagulation and Thrombosis Mechanisms (16 papers). Masashi Taki collaborates with scholars based in Japan, United States and Hong Kong. Masashi Taki's co-authors include Midori Shima, Keiji Nogami, Koichiro Yoneyama, Tadashi Matsushita, Katsuyuki Fukutake, Hideji Hanabusa, Tetsuji Sato, Hiroki Yoshida, Kazunobu Ouchi and Koichiro Sato and has published in prestigious journals such as New England Journal of Medicine, Blood and Biochemical and Biophysical Research Communications.

In The Last Decade

Masashi Taki

56 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

2016 326 citations Midori Shima, Hideji Hanabusa et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Masashi Taki

Since Specialization

Citations

This map shows the geographic impact of Masashi Taki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masashi Taki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masashi Taki more than expected).

Fields of papers citing papers by Masashi Taki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masashi Taki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masashi Taki. The network helps show where Masashi Taki may publish in the future.

Co-authorship network of co-authors of Masashi Taki

This figure shows the co-authorship network connecting the top 25 collaborators of Masashi Taki. A scholar is included among the top collaborators of Masashi Taki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masashi Taki. Masashi Taki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, phase IV clinical study 2022 ·BMJ Open ·Midori Shima, Hideyuki Takedani, (unknown), Masashi Taki, Akira Ishiguro, (unknown), (unknown), (unknown), Seitaro Yoshida, Keiji Nogami	4
2	Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial 2022 ·BMJ Open ·Kenichi Ogiwara, Masashi Taki, Takashi Suzuki, Hideyuki Takedani, Tadashi Matsushita, Kagehiro Amano, Masanori Matsumoto, Kenji Nishio, Midori Shima, Masato Kasahara, Keiji Nogami	5
3	Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan 2018 ·International Journal of Hematology ·Masashi Taki, Katsuyuki Fukutake, Tadashi Matsushita, Keiji Nogami, Midori Shima, Akira Yoshioka, Junki Takamatsu, Morio Arai, Hiroshi Takagi, (unknown), Werner Engl, Akira Shirahata	4
4	Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations 2017 ·International Journal of Hematology ·Keiji Nogami, Midori Shima, Katsuyuki Fukutake, Teruhisa Fujii, Masashi Taki, Tadashi Matsushita, Satoshi Higasa, Tetsuji Sato, Michio Sakai, Morio Arai, (unknown), Werner Engl, Brigitt E. Abbuehl, Barbara A. Konkle	7
5	Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A breakdown → 2016 ·New England Journal of Medicine ·Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, (unknown), Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami	326
6	The International Immune Tolerance Induction Study and its follow-up study on Japanese hemophilia A patients with inhibitors 2015 ·International Journal of Hematology ·Akira Yoshioka, (unknown), (unknown), Ikuya Usami, Masao Kobayashi, Ryōji Kobayashi, Manabu Sotomatsu, Akira Shirahata, Takashi Suzuki, Masashi Taki, Yasushi Ishida, Tadashi Matsushita, Midori Shima, Keiji Nogami, Michio Sakai, Hisato Kigasawa, Katsuyuki Fukutake	3
7	The prevalence of neutralizing antibodies against adeno‐associated virus capsids is reduced in young Japanese individuals 2013 ·Journal of Medical Virology ·Jun Mimuro, Hiroaki Mizukami, Midori Shima, Tadashi Matsushita, Masashi Taki, (unknown), Satoshi Higasa, Michio Sakai, Tsukasa Ohmori, Seiji Madoiwa, Keiya Ozawa, Yoichi Sakata	62
8	Methodological issue of assay for inhibitors to factor VIII/IX 2010 ·Japanese Journal of Thrombosis and Hemostasis ·Satoshi Yamazaki, Masashi Taki	1
9	Diagnosis and treatment for miscellaneous congenital coagulation factor deficiencies 2010 ·Japanese Journal of Thrombosis and Hemostasis ·(unknown), Masashi Taki	5
10	A Nationwide Survey of Childhood Idiopathic Thrombocytopenic Purpura in 2006 2008 ·Takuma Miura, (unknown), Eiichi Ishii, (unknown), Shigeru Ohta, Masashi Taki, Masue Imaizumi, Toshiaki Oka, Michiko Kajiwara, Junichi Kitazawa, Masaru Kubota, Yukihiro Takahashi, Fumio Bessho, Akira Shirahata	2
11	Methodological characteristics of Factor VIII : C inhibitor assays and the availability of inactivation treatment 2008 ·Japanese Journal of Thrombosis and Hemostasis ·Satoshi Yamazaki, Noriko Suzuki, Noriko Yamazaki, (unknown), (unknown), (unknown), (unknown), Masashi Taki	1
12	Neutralization effect of heparinase by thrombin generation test for the assessment of blood samples containing heparin 2008 ·Japanese Journal of Thrombosis and Hemostasis ·(unknown), (unknown), (unknown), (unknown), Satoshi Yamazaki, (unknown), Masashi Taki	1
13	Long-term safety and efficacy of recombinant activated factor VII (NovoSeven) in haemophilia patients with inhibitors: interim post marketing study analysis of 5 patient exposure years 2006 ·Japanese Journal of Thrombosis and Hemostasis ·Akira Shirahata, Toshiaki Oka, Katsuyuki Fukutake, Morio Arai, Hideji Hanabusa, Masashi Taki, Takeshi Nagao, J Mimaya, Nobuhiko Haga, Junki Takamatsu, Tadashi Kamiya, Midori Shima, Eizo Kakishita, Hideyuki Takedani, Noboru Takata, Masao Kobayashi, Tatsumi Uchida, (unknown), Akira Yoshioka	3
14	Consensus Guideline for Diagnosis and Treatment of Childhood Idiopathic Thrombocytopenic Purpura 2006 ·International Journal of Hematology ·Akira Shirahata, Eiichi Ishii, Haruhiko Eguchi, (unknown), Shigeru Ohta, Takashi Kaneko, (unknown), Masahiro Sako, Isao Sekine, Yukihiro Takahashi, Masashi Taki, Shigeru Tsuchiya, (unknown), Fumio Bessho, Yasuo Horikoshi, (unknown), J Akatsuka, Sumio Miyazaki	17
15	Successful treatment with vincristine of an infant with intractable Kasabach–Merritt syndrome 2006 ·Pediatrics International ·Masashi Taki, (unknown), (unknown), Miwako Kobayashi, Noriaki Kobayashi, (unknown), Takeshi Horiuchi, (unknown), Yasuo Horikoshi, J Mimaya	12
16	HLA-B Polymorphism in Japanese HIV-1–Infected Long-Term Surviving Hemophiliacs 2005 ·Viral Immunology ·(unknown), Hiroshi Terunuma, Megumi Takahashi, Hideji Hanabusa, Takuma Miura, Shu‐ichi Ikeda, Michio Sakai, Teruhisa Fujii, Yoshihiro Takahashi, Shinichi Oka, Juzo Matsuda, Masaaki Ishikawa, Masashi Taki, (unknown), J Mimaya, Masahiko Ito, Akinori Kimura, Michio Yasunami	12
17	Increasing Incidence of Critical Liver Disease among Causes of Death in Japanese Hemophiliacs with HIV-1 2004 ·Acta Haematologica ·Shinobu Tatsunami, Masashi Taki, Akira Shirahata, J Mimaya, Kaneo Yamada	15
18	A New Glucose-6-Phosphate Dehydrogenase Variant G6PD Sugao (826C→T) Exhibiting Chronic Hemolytic Anemia With Episodes of Hemolytic Crisis Immediately After Birth 2001 ·International Journal of Hematology ·Masashi Taki, Akira Hirono, (unknown), (unknown), (unknown), (unknown), Kaneo Yamada, (unknown), Shiro Miwa	5
19	Partial nucleotide sequencing of the NS3/helicase region of hepatitis G virus to prove vertical transmission 1999 ·FEMS Microbiology Letters ·(unknown), Takuma Miura, (unknown), Masashi Taki, (unknown), Shunji Sugii, Kunitada Shimotohno	3
20	Frequent Detection of Hepatitis C Virus US Strain in Japanese Hemophiliacs 1990 ·Japanese Journal of Cancer Research ·Makoto Hijikata, Nobuyuki Kato, Shigehisa Mori, Yuko Ootsuyama, Masanori Nakagawa, Takashi Sügimura, (unknown), Hideo Kojima, Takashi Meguro, Masashi Taki, (unknown), Kaneo Yamada, Kunitada Shimotohno	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact